Edition:
United States

People: Arrowhead Pharmaceuticals Inc (ARWR.O)

ARWR.O on Nasdaq

5.74USD
4 May 2016
Change (% chg)

$-0.07 (-1.20%)
Prev Close
$5.81
Open
$5.74
Day's High
$5.87
Day's Low
$5.66
Volume
479,079
Avg. Vol
762,205
52-wk High
$9.36
52-wk Low
$3.07

Search Stocks

Ferrari, Mauro 

Dr. Mauro Ferrari, Ph.D., is Independent Director of Arrowhead Research Corp. Dr. Ferrari is the President and CEO of The Houston Methodist Hospital Research Institute (TMHRI), Executive Vice President of Houston Methodist Hospital, and Senior Associate Dean of Weill Cornell Medical College in New York. He is also the President of The Alliance for NanoHealth. Dr. Ferrari is an internationally recognized expert in nanomedicine and biomedical nanotechnology. Prior to assuming leadership of TMHRI, Dr. Ferrari was Professor and Chairman of The Department of NanoMedicine and Biomedical Engineering at The University of Texas Health Science Center at Houston, Professor of Experimental Therapeutics at the MD Anderson Cancer Center, Adjunct Professor of Bioengineering at Rice University, and Adjunct Professor of Biomedical Engineering at the University of Texas in Austin. His previous academic appointments include tenured professorships at UC Berkeley and The Ohio State University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Douglas Given

--

Christopher Anzalone

2,319,760

Kenneth Myszkowski

1,074,100

Bruce Given

2,128,870

David Lewis

863,439

Peter Leone

679,669
As Of  29 Sep 2015
Search Stocks